Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DISP-10 · 1 trial · 4 indications
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0
To select the Recommended Dose for Expansion (RDE) for Part 2
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| DISP-10 | EXPERIMENTAL | Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel. |
| Name | Type | Description |
|---|---|---|
| DISP-10 | BIOLOGICAL | Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration. |
Key Inclusion Criteria: 1. Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma 2. Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy 3. Eastern Cooperative O...
Top 20 of 76 competitors
DISP-10 is an investigational monoclonal antibody being studied for the treatment of colorectal cancer. It is currently in Phase 1 clinical development, with an active trial enrolling participants who have advanced gastrointestinal cancers, including colorectal cancer.
DISP-10 is a monoclonal antibody designed to target a specific biomarker in patients with advanced gastrointestinal cancers. The Phase 1 trial is biomarker-selected, meaning participants are chosen based on the presence of this molecular target.
DISP-10 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol BMY.
DISP-10 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is currently being evaluated in an early-stage clinical trial for safety and dosing.
DISP-10 is being studied in a Phase 1 clinical trial identified as NCT07544589, titled 'A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers.' The trial is recruiting in the United States and plans to enroll 66 participants.
DISP-10 is the primary name for this investigational monoclonal antibody. No alternative names have been reported for this drug in the available clinical trial information.